Literature DB >> 22920732

Monoclonal antibody therapeutics: history and future.

Nicholas A P S Buss1, Simon J Henderson, Mary McFarlane, Jacintha M Shenton, Lolke de Haan.   

Abstract

Over the last three decades, monoclonal antibodies have made a dramatic transformation from scientific tools to powerful human therapeutics. At present, approximately 30 therapeutic monoclonal antibodies are marketed in the United States and Europe in a variety of indications, with sales in the US alone reaching approximately $18.5 billion in 2010. This review describes how antibody engineering has revolutionized drug discovery and what are considered the key areas for future development in the monoclonal antibody therapy field.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22920732     DOI: 10.1016/j.coph.2012.08.001

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  88 in total

1.  Development of a stable low-dose aglycosylated antibody formulation to minimize protein loss during intravenous administration.

Authors:  Sorina Morar-Mitrica; Manasi Puri; Alexandra Beumer Sassi; Joshua Fuller; Ping Hu; George Crotts; Douglas Nesta
Journal:  MAbs       Date:  2015       Impact factor: 5.857

2.  A novel screening method to assess developability of antibody-like molecules.

Authors:  Neeraj Kohli; Nidhi Jain; Melissa L Geddie; Maja Razlog; Lihui Xu; Alexey A Lugovskoy
Journal:  MAbs       Date:  2015       Impact factor: 5.857

Review 3.  Aptamers as Therapeutic Agents: Has the Initial Euphoria Subsided?

Authors:  S K Haßel; G Mayer
Journal:  Mol Diagn Ther       Date:  2019-06       Impact factor: 4.074

4.  Quantification of the IgG2/4 kappa Monoclonal Therapeutic Eculizumab from Serum Using Isotype Specific Affinity Purification and Microflow LC-ESI-Q-TOF Mass Spectrometry.

Authors:  Paula M Ladwig; David R Barnidge; Maria A V Willrich
Journal:  J Am Soc Mass Spectrom       Date:  2016-12-21       Impact factor: 3.109

5.  Emerging trends and new developments in monoclonal antibodies: A scientometric analysis (1980-2016).

Authors:  Yunfeng Lai; Ruibing Wang; Xin Chen; Daisheng Tang; Yuanjia Hu; Jing Cai; Qingwen Zhang; Hao Hu
Journal:  Hum Vaccin Immunother       Date:  2017-02-21       Impact factor: 3.452

6.  Online Hydrophobic Interaction Chromatography-Mass Spectrometry for the Analysis of Intact Monoclonal Antibodies.

Authors:  Bifan Chen; Ziqing Lin; Andrew J Alpert; Cexiong Fu; Qunying Zhang; Wayne A Pritts; Ying Ge
Journal:  Anal Chem       Date:  2018-06-04       Impact factor: 6.986

Review 7.  Developing therapeutic antibodies for neurodegenerative disease.

Authors:  Y Joy Yu; Ryan J Watts
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

8.  Introduction to the series of reviews on "Antibody derivatives as new therapeutics for hematologic malignancies".

Authors:  Crystal L Mackall
Journal:  Blood       Date:  2014-02-26       Impact factor: 22.113

9.  CD4+ levels control the odds of induction of humoral immune responses to tracer doses of therapeutic antibodies.

Authors:  Sharat Srinivasula; Erin Gabriel; Insook Kim; Paula DeGrange; Alexis St Claire; Candace Mallow; Robert E Donahue; Chang Paik; H C Lane; Michele Di Mascio
Journal:  PLoS One       Date:  2017-11-09       Impact factor: 3.240

Review 10.  Mass spectrometry for the biophysical characterization of therapeutic monoclonal antibodies.

Authors:  Hao Zhang; Weidong Cui; Michael L Gross
Journal:  FEBS Lett       Date:  2013-11-26       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.